Proceeds from the financing are set to go toward expanding its capacity and investing in technologies designed to complement and extend its proprietary antibody discovery engine, as well as toward expanding its staff and facilities . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge